Renaissance Technologies
CMPI

Renaissance Technologies’s Checkmate Pharmaceuticals, Inc. Common Stock CMPI Stock Holding History

Renaissance Technologies’s Portfolio CMPI Stock Details CMPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,667
Closed -$42K – 4348
2021
Q3 		$42K Sell
10,667
-12,833
-55% -$66K ﹤0.01% 3385
2021
Q2 		$140K Buy
+23,500
New +$166K ﹤0.01% 3316

Other funds holding CMPI

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Renaissance Technologies's CMPI Position: Q4 2021 in Review

Renaissance Technologies sold out of Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) in Q4 2021, closing a stake of 10,667 shares — an estimated $42K sold.

Renaissance Technologies first reported a position in CMPI in Q2 2021 and held it in 2 quarters. The position peaked at $140K in Q2 2021. 25 funds tracked by Wall St. Rank hold CMPI as of Q4 2021.

  • Renaissance Technologies reported no remaining Checkmate Pharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Renaissance Technologies sold 10,667 Checkmate Pharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $42K.
  • Renaissance Technologies first reported a position in Checkmate Pharmaceuticals, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • Renaissance Technologies's Checkmate Pharmaceuticals, Inc. Common Stock position peaked at $140K in Q2 2021.
  • 25 funds tracked by Wall St. Rank held Checkmate Pharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on Renaissance Technologies's 13F filing for Q4 2021, filed 11 Feb 2022.